WO2007011601A2 - Cancer treatment using viruses, fluoropyrimidines and camptothecins - Google Patents
Cancer treatment using viruses, fluoropyrimidines and camptothecins Download PDFInfo
- Publication number
- WO2007011601A2 WO2007011601A2 PCT/US2006/027018 US2006027018W WO2007011601A2 WO 2007011601 A2 WO2007011601 A2 WO 2007011601A2 US 2006027018 W US2006027018 W US 2006027018W WO 2007011601 A2 WO2007011601 A2 WO 2007011601A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- irinotecan
- ndv
- fluoropyrimidine
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2612949A CA2612949C (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
JP2008521556A JP5190958B2 (en) | 2005-07-14 | 2006-07-12 | Treatment of cancer using viruses, fluoropyrimidine and camptothecin |
NZ562951A NZ562951A (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination |
EP06774644A EP1907015B1 (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
AU2006270297A AU2006270297B2 (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US11/913,362 US7767200B2 (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
CN2006800198745A CN101400368B (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
MX2007015407A MX2007015407A (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins. |
AT06774644T ATE540698T1 (en) | 2005-07-14 | 2006-07-12 | CANCER TREATMENT WITH VIRUSES, FLUOROPYRIMIDINES AND CAMPTOTHECINES |
IL186730A IL186730A0 (en) | 2005-07-14 | 2007-10-17 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
US12/839,829 US20110117060A1 (en) | 2005-07-14 | 2010-07-20 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69919505P | 2005-07-14 | 2005-07-14 | |
US60/699,195 | 2005-07-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/839,829 Division US20110117060A1 (en) | 2005-07-14 | 2010-07-20 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007011601A2 true WO2007011601A2 (en) | 2007-01-25 |
WO2007011601A3 WO2007011601A3 (en) | 2007-11-08 |
Family
ID=37669342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/027018 WO2007011601A2 (en) | 2005-07-14 | 2006-07-12 | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
Country Status (14)
Country | Link |
---|---|
US (2) | US7767200B2 (en) |
EP (1) | EP1907015B1 (en) |
JP (1) | JP5190958B2 (en) |
KR (1) | KR20080039344A (en) |
CN (1) | CN101400368B (en) |
AT (1) | ATE540698T1 (en) |
AU (1) | AU2006270297B2 (en) |
CA (1) | CA2612949C (en) |
IL (1) | IL186730A0 (en) |
MX (1) | MX2007015407A (en) |
NZ (1) | NZ562951A (en) |
RU (1) | RU2435586C2 (en) |
WO (1) | WO2007011601A2 (en) |
ZA (1) | ZA200708840B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143468A1 (en) * | 2008-05-22 | 2009-11-26 | Uti Limited Partnership | Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy |
US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070207149A1 (en) | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US7900230B2 (en) * | 2005-04-01 | 2011-03-01 | The Directv Group, Inc. | Intelligent two-way switching network |
US7991348B2 (en) | 2005-10-12 | 2011-08-02 | The Directv Group, Inc. | Triple band combining approach to satellite signal distribution |
US8019275B2 (en) | 2005-10-12 | 2011-09-13 | The Directv Group, Inc. | Band upconverter approach to KA/KU signal distribution |
RU2496873C1 (en) * | 2012-06-04 | 2013-10-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (НГУ) | STRAIN OF ENTEROVIRUS COXSACKIE B6 SELECTIVELY INFECTING AND LYSING TUMOROUS HUMAN CELLS in vitro |
CN112773812A (en) * | 2020-12-30 | 2021-05-11 | 烟台大学 | Application of novel camptothecin derivative in preparation of antitumor drugs |
CN112704683A (en) * | 2020-12-30 | 2021-04-27 | 烟台大学 | Novel camptothecin derivative and application thereof in preparing antitumor drugs |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (en) * | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | Novel camptothecin derivative |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
ES2196026T3 (en) * | 1993-04-30 | 2003-12-16 | Wellstat Biologics Corp | USE OF NDV IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CANCER. |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
CA2234060A1 (en) * | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
ATE301659T1 (en) | 1995-11-02 | 2005-08-15 | Osi Pharm Inc | METHOD FOR PRODUCING CAMPOTHECINE DERIVATIVES |
GB9600438D0 (en) | 1996-01-10 | 1996-03-13 | Pharmacia Spa | Hexacyclic camptothecin analogues, and process for preparing them |
GB9601779D0 (en) | 1996-01-30 | 1996-04-03 | Pharmacia Spa | 9, 10 Disubstituted camptothecin derivatives |
GB9702807D0 (en) | 1997-02-12 | 1997-04-02 | Pharmacia & Upjohn Spa | Alkynyl-substituted camptothecins and process for their preparation |
GB9715821D0 (en) | 1997-07-25 | 1997-10-01 | Pharmacia & Upjohn Spa | Amidino-camptothecin derivatives |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
GB9721070D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Bioactive derivatives of camptothecin |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
CZ295775B6 (en) | 1998-08-05 | 2005-11-16 | Aventis Pharma S. A. | Orally administrable agent for restricting or suppressing secondary gastrointestinal effects caused by administration camptothecin derivatives |
DE69901379T2 (en) | 1999-03-09 | 2002-11-07 | Sigma Tau Ind Farmaceuti | Camptothecin derivatives with anti-tumor effects |
US6428968B1 (en) * | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
MXPA01010393A (en) | 1999-04-15 | 2004-04-02 | Pro Virus Inc | Treatment of neoplasms with viruses. |
AU4564200A (en) * | 1999-04-29 | 2000-11-17 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
DE60131498T8 (en) * | 2000-02-02 | 2009-01-29 | Anges Mg Inc., Toyonaka | VIRUS COVENANT FOR GENERAL TRANSMISSION |
AU2001240658A1 (en) | 2000-02-29 | 2001-09-12 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
AU2001247513A1 (en) | 2000-03-17 | 2001-10-03 | Cell Therapeutics, Inc. | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US6911200B2 (en) * | 2000-03-24 | 2005-06-28 | Cell Genesys, Inc. | Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation |
GB0008928D0 (en) | 2000-04-11 | 2000-05-31 | Pharmacia & Upjohn Spa | A method of administering an antitumour compound |
CA2409932A1 (en) * | 2000-06-01 | 2001-12-06 | Sloan-Kettering Institute For Cancer Research | Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
AR035227A1 (en) * | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | USE OF A CHEMOTHERAPEUTIC AGENT FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE SENSITIZATION OF NEOPLASSIC CELLS RESISTANT TO CHEMOTHERAPEUTIC AGENTS WITH REOVIRUS |
US7348003B2 (en) * | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
US20040253272A1 (en) * | 2001-08-02 | 2004-12-16 | Yasufumi Kaneda | Process for producing inactivated virus envelopes |
IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
WO2005113013A2 (en) | 2004-05-20 | 2005-12-01 | Theravir Management L.P. | Compositions of ndv and methods of use thereof for treatment of cancer |
US7615209B2 (en) * | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
TW200306314A (en) | 2002-04-16 | 2003-11-16 | Tanabe Seiyaku Co | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
US6593334B1 (en) | 2002-05-02 | 2003-07-15 | The University Of North Carolina At Chapel Hill | Camptothecin-taxoid conjugates as antimitotic and antitumor agents |
ITRM20020306A1 (en) | 2002-05-31 | 2003-12-01 | Sigma Tau Ind Farmaceuti | ESTERS IN POSITION 20 OF CAMPTOTECINE. |
AU2003243380A1 (en) | 2002-06-03 | 2003-12-19 | California Pacific Medical Center | Nitrogen-based homo-camptothecin derivatives |
US20040034050A1 (en) | 2002-06-03 | 2004-02-19 | Yang Li-Xi | Homo-camptothecin derivatives |
EP1539230A4 (en) | 2002-06-21 | 2007-10-31 | Wellstat Biologics Corp | Administration of therapeutic viruses |
US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
EP1568379A1 (en) * | 2002-11-01 | 2005-08-31 | Genomidea Inc | Medicinal preparation having chemotherapeutic encapsulated therein |
US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
US20060018884A1 (en) | 2003-11-25 | 2006-01-26 | United Cancer Research Institute | Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
US20070207149A1 (en) * | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
MXPA06013902A (en) | 2004-05-28 | 2007-01-26 | Pfizer Prod Inc | Method for treating abnormal cell growth. |
-
2006
- 2006-07-12 CA CA2612949A patent/CA2612949C/en not_active Expired - Fee Related
- 2006-07-12 US US11/913,362 patent/US7767200B2/en active Active
- 2006-07-12 NZ NZ562951A patent/NZ562951A/en not_active IP Right Cessation
- 2006-07-12 CN CN2006800198745A patent/CN101400368B/en not_active Expired - Fee Related
- 2006-07-12 EP EP06774644A patent/EP1907015B1/en not_active Not-in-force
- 2006-07-12 RU RU2008105603/15A patent/RU2435586C2/en not_active IP Right Cessation
- 2006-07-12 WO PCT/US2006/027018 patent/WO2007011601A2/en active Application Filing
- 2006-07-12 KR KR1020077030035A patent/KR20080039344A/en not_active Application Discontinuation
- 2006-07-12 MX MX2007015407A patent/MX2007015407A/en active IP Right Grant
- 2006-07-12 JP JP2008521556A patent/JP5190958B2/en not_active Expired - Fee Related
- 2006-07-12 AT AT06774644T patent/ATE540698T1/en active
- 2006-07-12 AU AU2006270297A patent/AU2006270297B2/en not_active Ceased
-
2007
- 2007-10-16 ZA ZA200708840A patent/ZA200708840B/en unknown
- 2007-10-17 IL IL186730A patent/IL186730A0/en not_active IP Right Cessation
-
2010
- 2010-07-20 US US12/839,829 patent/US20110117060A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
None |
See also references of EP1907015A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143468A1 (en) * | 2008-05-22 | 2009-11-26 | Uti Limited Partnership | Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy |
KR20110029129A (en) * | 2008-05-22 | 2011-03-22 | 김만복 | Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy |
KR101585702B1 (en) * | 2008-05-22 | 2016-01-15 | 제일약품주식회사 | Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy |
US8377450B2 (en) | 2009-11-30 | 2013-02-19 | United Cancer Research Institute | Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
Also Published As
Publication number | Publication date |
---|---|
RU2435586C2 (en) | 2011-12-10 |
CN101400368A (en) | 2009-04-01 |
NZ562951A (en) | 2011-09-30 |
JP5190958B2 (en) | 2013-04-24 |
EP1907015A4 (en) | 2009-03-18 |
RU2008105603A (en) | 2009-08-20 |
CA2612949C (en) | 2015-04-28 |
AU2006270297B2 (en) | 2013-01-17 |
WO2007011601A3 (en) | 2007-11-08 |
MX2007015407A (en) | 2008-02-19 |
US20110117060A1 (en) | 2011-05-19 |
KR20080039344A (en) | 2008-05-07 |
US7767200B2 (en) | 2010-08-03 |
EP1907015B1 (en) | 2012-01-11 |
AU2006270297A1 (en) | 2007-01-25 |
US20080193419A1 (en) | 2008-08-14 |
CA2612949A1 (en) | 2007-01-25 |
JP2009501230A (en) | 2009-01-15 |
CN101400368B (en) | 2012-10-03 |
IL186730A0 (en) | 2008-02-09 |
EP1907015A2 (en) | 2008-04-09 |
ATE540698T1 (en) | 2012-01-15 |
ZA200708840B (en) | 2008-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110117060A1 (en) | Cancer treatment using viruses, fluoropyrimidines and camptothecins | |
US9844574B2 (en) | Cancer treatment using viruses and camptothecins | |
AU2003243307B2 (en) | Administration of therapeutic viruses | |
US20020071832A1 (en) | Use of mutant herpes viruses and anticancer agents in the treatment of cancer | |
Pazdur et al. | Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hour continuous infusion weekly for three weeks in metastatic colorectal carcinoma | |
EP1486212A1 (en) | Combination of a mutant herepes virus and irinotecan for the treatment of cancer | |
AU2004233804A1 (en) | Treating hepatocellular carcinomas using therapeutic viruses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680019874.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 186730 Country of ref document: IL Ref document number: 2006270297 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 562951 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11913362 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/015407 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2008521556 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2612949 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077030035 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008105603 Country of ref document: RU Ref document number: 2006774644 Country of ref document: EP |